{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:24:12Z","timestamp":1770459852109,"version":"3.49.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10637-022-01262-2","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T12:03:56Z","timestamp":1654517036000},"page":"1350-1353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A novel SLC8A1\/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report"],"prefix":"10.1007","volume":"40","author":[{"given":"Chunguang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianru","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"issue":"5","key":"1262_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jtho.2016.03.012","volume":"11","author":"AS Tsao","year":"2015","unstructured":"Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS et al (2015) Scientific Advances in Lung Cancer 2015. J Thorac Oncol 11(5):613\u2013638. https:\/\/doi.org\/10.1016\/j.jtho.2016.03.012","journal-title":"J Thorac Oncol"},{"issue":"28","key":"1262_CR2","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","volume":"34","author":"T Yoshida","year":"2016","unstructured":"Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, Sakao Y, Hida T, Yatabe Y (2016) Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol 34(28):3383\u20133389. https:\/\/doi.org\/10.1200\/JCO.2015.65.8732","journal-title":"J Clin Oncol"},{"key":"1262_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.lungcan.2018.05.020","volume":"122","author":"JE Chaft","year":"2018","unstructured":"Chaft JE, Dagogo-Jack I, Santini FC, Eng J, Yeap BY, Izar B, Chin E, Jones DR, Kris MG, Shaw AT et al (2018) Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer 122:67\u201371. https:\/\/doi.org\/10.1016\/j.lungcan.2018.05.020","journal-title":"Lung Cancer"},{"issue":"36","key":"1262_CR4","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2217\/fon-2020-0597","volume":"16","author":"J Zeng","year":"2020","unstructured":"Zeng J, Cui X, Cheng L, Chen Y, Du X, Sheng L (2020) Micropapillary pattern of stage IIIA-N(2) lung adenocarcinoma is a prognostic factor after adjuvant chemoradiotherapy. Future Oncol 16(36):3075\u20133084. https:\/\/doi.org\/10.2217\/fon-2020-0597","journal-title":"Future Oncol"},{"key":"1262_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.lungcan.2020.12.018","volume":"152","author":"C Cai","year":"2021","unstructured":"Cai C, Tang Y, Li Y, Chen Y, Tian P, Wang Y, Gong Y, Peng F, Zhang Y, Yu M et al (2021) Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients. Lung Cancer 152:104\u2013108. https:\/\/doi.org\/10.1016\/j.lungcan.2020.12.018","journal-title":"Lung Cancer"},{"key":"1262_CR6","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.2147\/OTT.S319845","volume":"14","author":"X Zhu","year":"2021","unstructured":"Zhu X, He Y, Wang Y, Lei Y, Su X, Liu Y, Wu S, He Z (2021) Identification of a Novel SLC8A1-ALK Fusion and Non-Canonical Expression Significantly Responding to ALK-TKIs in Lung Adenocarcinoma: A Case Report. OncoTargets and therapy 14:4915\u20134920. https:\/\/doi.org\/10.2147\/OTT.S319845","journal-title":"OncoTargets and therapy"},{"issue":"1","key":"1262_CR7","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12967-021-02982-4","volume":"19","author":"P Xia","year":"2021","unstructured":"Xia P, Zhang L, Li P, Liu E, Li W, Zhang J, Li H, Su X, Jiang G (2021) Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers. J translational Med 19(1):308. https:\/\/doi.org\/10.1186\/s12967-021-02982-4","journal-title":"J translational Med"},{"issue":"2","key":"1262_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/JTO.0b013e3181c20080","volume":"5","author":"JA Boyd","year":"2010","unstructured":"Boyd JA, Hubbs JL, Kim DW, Hollis D, Marks LB, Kelsey CR (2010) Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure. J Thorac Oncol 5(2):211\u2013214. https:\/\/doi.org\/10.1097\/JTO.0b013e3181c20080","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1262_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","volume":"19","author":"WZ Zhong","year":"2018","unstructured":"Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L (2018) Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol 19(1):139\u2013148. https:\/\/doi.org\/10.1016\/S1470-2045(17)30729-5","journal-title":"Lancet Oncol"}],"updated-by":[{"DOI":"10.1007\/s10637-022-01292-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000}}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01262-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01262-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01262-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:51:03Z","timestamp":1678510263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01262-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1262"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01262-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10637-022-01292-w","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"assertion":[{"value":"1 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10637-022-01292-w","URL":"https:\/\/doi.org\/10.1007\/s10637-022-01292-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants comply with institutional and\/or National Research Council ethical standards and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"A written informed consent was obtained from the patient\u2019s family for publication of the case details.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}